Viral Infections in Lung Transplant Recipients

ABSTRACT

Viral infections, including β-herpes viruses and community respiratory viruses, are frequent pathogens in lung transplant recipients. These pathogens have become increasingly recognized as having a significant role in long-term outcomes of lung transplantation, which has been limited by the frequent development of infections, and chronic allograft dysfunction. Community respiratory viruses, such as influenza and respiratory syncytial virus have been associated with both acute rejection and chronic allograft dysfunction, particularly if early treatment was not administered. β-herpes viruses, particularly cytomegalovirus (CMV), have long been associated with increased mortality in lung transplant recipients, although the advent of effective antiviral strategies has led to improved morbidity and mortality. Because these pathogens have been associated with altered immune responses against the allograft, a better understanding of immunopathogenesis of viral infections may lead to a broader approach to limit the morbidity from these pathogens.

KEYWORDS

Lung transplantation - respiratory virus - cytomegalovirus

REFERENCES

• 1 Trulock E P, Christie J D, Edwards L B et al.. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007.  J Heart Lung Transplant. 2007;  26 782-795
• 2 Kim Y J, Boeckh M, Englund J A. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection.  Semin Respir Crit Care Med. 2007;  28 222-242
• 3 Garbino J, Gerbase M W, Wunderli W et al.. Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact.  Am J Respir Crit Care Med. 2004;  170 1197-1203
• 4 Milstone A P, Brumble L M, Barnes J et al.. A single-season prospective study of respiratory viral infections in lung transplant recipients.  Eur Respir J. 2006;  28 131-137
• 5 Fan J, Henrickson K J, Savatski L L. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex).  Clin Infect Dis. 1998;  26 1397-1402
• 6 Weinberg A, Zamora M R, Li S, Torres F, Hodges T N. The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients.  J Clin Virol. 2002;  25 171-175
• 7 McCurdy L H, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin.  J Heart Lung Transplant. 2003;  22 745-753
• 8 Hopkins P, McNeil K, Kermeen F et al.. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus.  Am J Respir Crit Care Med. 2008;  178 876-881
• 9 Falsey A R, Formica M A, Walsh E E. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness.  J Clin Microbiol. 2002;  40 817-820
• 10 McIntosh K, McAdam A J. Human metapneumovirus—an important new respiratory virus.  N Engl J Med. 2004;  350 431-433
• 11 Vilchez R A, Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function.  Am J Transplant. 2003;  3 116-120
• 12 Mahalingam S, Schwarze J, Zaid A et al.. Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections?.  Microbes Infect. 2006;  8 285-293
• 13 Kurt-Jones E A, Popova L, Kwinn L et al.. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus.  Nat Immunol. 2000;  1 398-401
• 14 Sha Q, Truong-Tran A Q, Plitt J R, Beck L A, Schleimer R P. Activation of airway epithelial cells by toll-like receptor agonists.  Am J Respir Cell Mol Biol. 2004;  31 358-364
• 15 Delgado M F, Coviello S, Monsalvo A C et al.. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease.  Nat Med. 2009;  15 34-41
• 16 Graham B S, Rutigliano J A, Johnson T R. Respiratory syncytial virus immunobiology and pathogenesis.  Virology. 2002;  297 1-7
• 17 Crowe Jr J E, Williams J V. Immunology of viral respiratory tract infection in infancy.  Paediatr Respir Rev. 2003;  4 112-119
• 18 Castilow E M, Olson M R, Varga S M. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.  Immunol Res. 2007;  39 225-239
• 19 Olson M R, Varga S M. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease.  J Immunol. 2007;  179 5415-5424
• 20 Tsitsikas D A, Oakervee H, Cavenagh J D, Gribben J, Agrawal S G, Mattes F M. Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience.  Br J Haematol. 2009;  146 574-576
• 21 Sparrelid E, Ljungman P, Ekelöf-Andström E et al.. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections.  Bone Marrow Transplant. 1997;  19 905-908
• 22 Liu V, Dhillon G S, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.  Transpl Infect Dis. 2009;  , Sep 15. [Epub ahead of print]
• 23 Pelaez A, Lyon G M, Force S D et al.. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection.  J Heart Lung Transplant. 2009;  28 67-71
• 24 Glanville A R, Scott A I, Morton J M et al.. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation.  J Heart Lung Transplant. 2005;  24 2114-2119
• 25 Nokes J D, Cane P A. New strategies for control of respiratory syncytial virus infection.  Curr Opin Infect Dis. 2008;  21 639-643
• 26 Zhang W, Tripp R A. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.  J Virol. 2008;  82 12221-12231
• 27 Garantziotis S, Howell D N, McAdams H P, Davis R D, Henshaw N G, Palmer S M. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome.  Chest. 2001;  119 1277-1280
• 28 Vilchez R, McCurry K, Dauber J et al.. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients.  Transplantation. 2002;  73 1075-1078
• 29 Hoft D F, Belshe R B. The genetic archaeology of influenza.  N Engl J Med. 2004;  351 2550-2551
• 30 Centers for Disease Control and Prevention (CDC) . Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009.  MMWR Morb Mortal Wkly Rep. 2009;  58 893-896
• 31 Danziger-Isakov L A, Husain S, Mooney M L, Hannan M M. ISHLT Infectious Diseases Council . The novel 2009 H1N1 influenza virus pandemic: unique considerations for programs in cardiothoracic transplantation.  J Heart Lung Transplant. 2009;  28 1341-1347
• 32 Faix D J, Sherman S S, Waterman S H. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans.  N Engl J Med. 2009;  361 728-729
• 33 Le Goffic R, Pothlichet J, Vitour D et al.. Cutting edge: influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells.  J Immunol. 2007;  178 3368-3372
• 34 Mauad T, Hajjar L A, Callegari G D et al.. Lung pathology in fatal novel human influenza A (H1N1) infection.  Am J Respir Crit Care Med. 2010;  181 72-79
• 35 McKinstry K K, Strutt T M, Buck A et al.. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge.  J Immunol. 2009;  182 7353-7363
• 36 Sun J, Madan R, Karp C L, Braciale T J. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10.  Nat Med. 2009;  15 277-284
• 37 Vilchez R A, McCurry K, Dauber J et al.. Influenza virus infection in adult solid organ transplant recipients.  Am J Transplant. 2002;  2 287-291
• 38 Kuo J H, Hwang R. Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: effect of protective agents (polyethyleneimine and sugars) on the stability of DNA.  J Pharm Pharmacol. 2004;  56 27-33
• 39 Vilchez R A, McCurry K, Dauber J et al.. The epidemiology of parainfluenza virus infection in lung transplant recipients.  Clin Infect Dis. 2001;  33 2004-2008
• 40 Moudgil A, Bagga A, Toyoda M, Nicolaidou E, Jordan S C, Ross D. Expression of gamma-IFN mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung transplant recipients.  Clin Transplant. 1999;  13 201-207
• 41 Winter J B, Gouw A S, Groen M, Wildevuur C, Prop J. Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts.  Transplantation. 1994;  57 418-422
• 42 Walter M J, Kajiwara N, Karanja P, Castro M, Holtzman M J. Interleukin 12 p40 production by barrier epithelial cells during airway inflammation.  J Exp Med. 2001;  193 339-351
• 43 Hayney M S, Moran J, Wiegert N A, Burlingham W J. Lung transplant patients' T cell responses to influenza vaccine viruses between seasons.  Vaccine. 2008;  26 2596-2600
• 44 Mazzone P J, Mossad S B, Mawhorter S D, Mehta A C, Schilz R J, Maurer J R. The humoral immune response to influenza vaccination in lung transplant patients.  Eur Respir J. 2001;  18 971-976
• 45 Khazeni N, Bravata D M, Holty J E, Uyeki T M, Stave C D, Gould M K. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza.  Ann Intern Med. 2009;  151 464-473
• 46 Ison M G, Sharma A, Shepard J A, Wain J C, Ginns L C. Outcome of influenza infection managed with oseltamivir in lung transplant recipients.  J Heart Lung Transplant. 2008;  27 282-288
• 47 Khalifah A P, Hachem R R, Chakinala M M et al.. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death.  Am J Respir Crit Care Med. 2004;  170 181-187
• 48 Vilchez R A, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection—myth or reality?.  Am J Transplant. 2003;  3 245-249
• 49 Cooper J D, Billingham M, Egan T International Society for Heart and Lung Transplantation et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts.  J Heart Lung Transplant. 1993;  12 713-716
• 50 Kuo E, Bharat A, Goers T et al.. Respiratory viral infection in obliterative airway disease after orthotopic tracheal transplantation.  Ann Thorac Surg. 2006;  82 1043-1050
• 51 Welsh R M, Markees T G, Woda B A et al.. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody.  J Virol. 2000;  74 2210-2218
• 52 Rossini S, Casazza A P, Engelmann E C, Havaux M, Jennings R C, Soave C. Suppression of both ELIP1 and ELIP2 in Arabidopsis does not affect tolerance to photoinhibition and photooxidative stress.  Plant Physiol. 2006;  141 1264-1273
• 53 Fishman J A, Rubin R H. Infection in organ-transplant recipients.  N Engl J Med. 1998;  338 1741-1751
• 54 Taylor D O, Edwards L B, Boucek M M et al.. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report—2007.  J Heart Lung Transplant. 2007;  26 769-781
• 55 Manuel O, Kumar D, Moussa G et al.. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis.  Transplantation. 2009;  87 719-725
• 56 Staras S A, Dollard S C, Radford K W, Flanders W D, Pass R F, Cannon M J. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994.  Clin Infect Dis. 2006;  43 1143-1151
• 57 Gillespie G M, Wills M R, Appay V et al.. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors.  J Virol. 2000;  74 8140-8150
• 58 Balthesen M, Messerle M, Reddehase M J. Lungs are a major organ site of cytomegalovirus latency and recurrence.  J Virol. 1993;  67 5360-5366
• 59 Bonatti H, Tabarelli W, Ruttmann E et al.. Impact of cytomegalovirus match on survival after cardiac and lung transplantation.  Am Surg. 2004;  70 710-714
• 60 Soghikian M V, Valentine V G, Berry G J, Patel H R, Robbins R C, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.  J Heart Lung Transplant. 1996;  15 881-887
• 61 Duncan S R, Paradis I L, Yousem S A et al.. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients.  Am Rev Respir Dis. 1992;  146 1419-1425
• 62 Keenan R J, Lega M E, Dummer J S et al.. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation.  Transplantation. 1991;  51 433-438
• 63 Gandhi M K, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments.  Lancet Infect Dis. 2004;  4 725-738
• 64 Söderberg-Nauclér C, Fish K N, Nelson J A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors.  Cell. 1997;  91 119-126
• 65 Gold M C, Munks M W, Wagner M, Koszinowski U H, Hill A B, Fling S P. The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo.  J Immunol. 2002;  169 359-365
• 66 Gerna G, Lilleri D, Rognoni V et al.. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients.  Am J Transplant. 2009;  9 1142-1150
• 67 Weigt S S, Elashoff R M, Keane M P et al.. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation.  Am J Transplant. 2008;  8 1512-1522
• 68 Shlobin O A, West E E, Lechtzin N et al.. Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients.  J Immunol. 2006;  176 2625-2634
• 69 Gamadia L E, Remmerswaal E B, Weel J F, Bemelman F, van Lier R A, Ten Berge I J. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.  Blood. 2003;  101 2686-2692
• 70 Westall G P, Brooks A G, Kotsimbos T. CD8+ T-cell maturation following lung transplantation: the differential impact of CMV and acute rejection.  Transpl Immunol. 2007;  18 186-192
• 71 Pipeling M R, West E E, Osborne C M et al.. Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection.  J Immunol. 2008;  181 546-556
• 72 Kerschner H, Jaksch P, Karigl G, Popow-Kraupp T, Klepetko W, Puchhammer-Stöckl E. Cytomegalovirus DNA load patterns developing after lung transplantation are significantly correlated with long-term patient survival.  Transplantation. 2009;  87 1720-1726
• 73 Egan J J, Barber L, Lomax J et al.. Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients.  Thorax. 1995;  50 9-13
• 74 Guiver M, Fox A J, Mutton K, Mogulkoc N, Egan J. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients.  Transplantation. 2001;  71 1609-1615
• 75 Bhorade S M, Sandesara C, Garrity E R et al.. Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients.  J Heart Lung Transplant. 2001;  20 928-934
• 76 Weinberg A, Hodges T N, Li S, Cai G, Zamora M R. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation.  J Clin Microbiol. 2000;  38 768-772
• 77 Pang X L, Fox J D, Fenton J M, Miller G G, Caliendo A M, Preiksaitis J K. American Society of Transplantation Infectious Diseases Community of Practice . Interlaboratory comparison of cytomegalovirus viral load assays.  Am J Transplant. 2009;  9 258-268
• 78 Humar A. Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis.  Transplantation. 2006;  82(2, Suppl) S9-S14
• 79 Solans E P, Garrity Jr E R, McCabe M, Martinez R, Husain A N. Early diagnosis of cytomegalovirus pneumonitis in lung transplant patients.  Arch Pathol Lab Med. 1995;  119 33-35
• 80 Erice A, Hertz M I, Snyder L S, Englund J, Edelman C K, Balfour Jr H H. Evaluation of centrifugation cultures of bronchoalveolar lavage fluid for the diagnosis of cytomegalovirus pneumonitis.  Diagn Microbiol Infect Dis. 1988;  10 205-212
• 81 Chemaly R F, Yen-Lieberman B, Chapman J et al.. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients.  Am J Transplant. 2005;  5 544-548
• 82 Westall G P, Michaelides A, Williams T J, Snell G I, Kotsimbos T C. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients.  J Infect Dis. 2004;  190 1076-1083
• 83 Russo M J, Sternberg D I, Hong K N et al.. Postlung transplant survival is equivalent regardless of cytomegalovirus match status.  Ann Thorac Surg. 2007;  84 1129-1134, discussion 1134–1135
• 84 Duncan S R, Grgurich W F, Iacono A T et al.. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.  Am J Respir Crit Care Med. 1994;  150 146-152
• 85 Zamora M R. Cytomegalovirus and lung transplantation.  Am J Transplant. 2004;  4 1219-1226
• 86 Ruttmann E, Geltner C, Bucher B et al.. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.  Transplantation. 2006;  81 1415-1420
• 87 Chmiel C, Speich R, Hofer M et al.. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.  Clin Infect Dis. 2008;  46 831-839
• 88 Zamora M R, Nicolls M R, Hodges T N et al.. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation.  Am J Transplant. 2004;  4 1635-1642
• 89 Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation.  Transplantation. 1999;  67 315-320
• 90 Jaksch P, Zweytick B, Kerschner H et al.. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.  J Heart Lung Transplant. 2009;  28 670-675
• 91 Limaye A P, Corey L, Koelle D M, Davis C L, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.  Lancet. 2000;  356 645-649
• 92 Valantine H A, Luikart H, Doyle R et al.. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone.  Transplantation. 2001;  72 1647-1652
• 93 Weill D, Lock B J, Wewers D L et al.. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction.  Am J Transplant. 2003;  3 492-496
• 94 Thomas L D, Milstone A P, Miller G G, Loyd J E, Stephen Dummer J. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.  Clin Transplant. 2009;  23 476-483
• 95 Monforte V, Román A, Gavaldà J et al.. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.  Transplant Proc. 2005;  37 4039-4042
• 96 Limaye A P, Raghu G, Koelle D M, Ferrenberg J, Huang M L, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.  J Infect Dis. 2002;  185 20-27
• 97 Tamm M, Aboyoun C L, Chhajed P N, Rainer S, Malouf M A, Glanville A R. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome.  Am J Respir Crit Care Med. 2004;  170 1120-1123
• 98 Reddy A J, Zaas A K, Hanson K E, Palmer S M. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.  J Heart Lung Transplant. 2007;  26 1286-1292
• 99 Brestrich G, Zwinger S, Fischer A et al.. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy.  Am J Transplant. 2009;  9 1679-1684
• 100 Einsele H, Roosnek E, Rufer N et al.. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.  Blood. 2002;  99 3916-3922
• 101 Brestrich G, Zwinger S, Roemhild A et al.. Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy.  J Immunother. 2009;  32 932-940
• 102 Aris R M, Maia D M, Neuringer I P et al.. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.  Am J Respir Crit Care Med. 1996;  154(6 Pt 1) 1712-1717
• 103 Tsai D E, Douglas L, Andreadis C et al.. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial.  Am J Transplant. 2008;  8 1016-1024
• 104 Stevens S J, Verschuuren E A, Pronk I et al.. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients.  Blood. 2001;  97 1165-1171
• 105 Knoop C, Kentos A, Remmelink M et al.. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.  Clin Transplant. 2006;  20 179-187
• 106 Funch D P, Walker A M, Schneider G, Ziyadeh N J, Pescovitz M D. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients.  Am J Transplant. 2005;  5 2894-2900
• 107 Deborska-Materkowska D, Lewandowski Z, Sadowska A et al.. Fever, human herpesvirus-6 (HHV-6) seroconversion, and acute rejection episodes as a function of the initial seroprevalence for HHV-6 in renal transplant recipients.  Transplant Proc. 2006;  38 139-143
• 108 Kidd I M, Clark D A, Sabin C A et al.. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection.  Transplantation. 2000;  69 2400-2404
• 109 Neurohr C, Huppmann P, Leuchte H Munich Lung Transplant Group et al. Human herpesvirus 6 in bronchoalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome?.  Am J Transplant. 2005;  5 2982-2991
• 110 Ross D J, Chan R C, Kubak B, Laks H, Nichols W S. Bronchiolitis obliterans with organizing pneumonia: possible association with human herpesvirus-7 infection after lung transplantation.  Transplant Proc. 2001;  33 2603-2606
• 111 Christie J D, Edwards L B, Aurora P et al.. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report—2008.  J Heart Lung Transplant. 2008;  27 957-969